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“in medical research involving human subjects, the well-being 
of the individual research subject must take precedence over 
all other interests” 
Helsinki Declaration, clause 6 
     
The challenge from patient activism 
 
• 1960s onwards - activists question the 
right of the professional to make 
decisions for the patient 
• Citizens begin to think of access to 
healthcare as consumerism 
• This includes the exchange of 
commodities – human tissue, access to 
cohorts of patients become the basis of 
negotiation and exchange 
• Patients talk of the right to participate in 
research (as opposed to the duty 
mentioned above) 
 
The challenge from bioethics 
 
• There is a secure foundation of research ethics which we can now 
consider refining 
• Citizens have a duty to participate in research and are often willing to 
fulfil this duty 
• This should be extended to children – to exclude them is to deny them 
the right to fulfil their duties as citizens 
• Paternalistic restraints on research support the power difference 
between the researchers and the researched upon 
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Challenges to Helsinki Declaration 
 
Rationale and history 
 
In this work we look at how patient activism has led to charges that the ethics 
of research in clinical trials are too conservative and potentially restrictive of 
research that is seen as urgent and necessary.  We examine this problem 
from the perspective of active patients and patient advocates and argue for 
alternative approaches to what ought or ought not to be permitted.  
 
Historical Development 
  
Early examples of unethical trials conducted without regulation on 
uninformed and unwilling participants include the Tuskegee and Willowbrook 
scandals as well as the Nazi experiments. 
 
Exposure of these instances brought about the introduction and application 
of regulation and the gradual spread of research ethics which has resulted in 
the landscape of governance in place today. 
 
We note that there have been a number of recent challenges to this position 
and suggest that we now have a landscape where research is closely 
restricted and we have groups of research participants who are informed and 
willing.  We liken these changes to the swing of a pendulum. 
 
 
Reading 
Woods & McCormack, 2011, Disputing the ethics of research: the challenge from bioethics and 
patient activism to the interpretation of the Declaration of Helsinki in clinical trials (forthcoming) 
Rose & Novas, 2005, Biological Citizenship 
Harris & Holm, 2003, Should we presume moral turpitude in our children? Small children and 
consent to medical research 
Epstein, 1995, The Construction of Lay Expertise - AIDS Activism and the Forging of Credibility  
in the Reform of Clinical Trials   
Neuromuscular Disorders 
NMD patient organisations have inherited the activist legacy as a reaction to 
the ‘no hope, no help’ message of therapeutic nihilism and are helping to 
drive the research agenda. 
 
With reference to the Helsinki Declaration it can be argued that, for a person 
with a NMD, the right to participate in a clinical trial could be a condition of 
their well-being.  Concern for their well-being therefore becomes a reason to 
include, rather than exclude them, in clinical trials. 
  
Conclusions 
There are some problems with the ‘right to participate’ approach.  Patients 
may have the therapeutic misconception – the notion that the trial is a 
treatment – or they may want to take higher risks in a trial than society 
deems acceptable. 
 
The dialogue between people with NMDs, scientists, clinicians and ethicists 
should continue in order to reach a more nuanced understanding of people’s 
motivations and to help science progress in a timely manner. 
Declaration of Helsinki - Ethical Principles for Medical Research 
Involving Human Subjects 
 
The Declaration of Helsinki is widely used as the ethical basis of research 
governance.  It assumes a number of things about research subjects: 
 
• they are vulnerable 
• they are open to exploitation by the researcher 
• their welfare comes above all other considerations  
